TITLE

Relationship Between Age-Related Macular Degeneration--Associated Variants of Complement Factor H and LOC387715 With Coronary Artery Disease

AUTHOR(S)
Pulido, Jose S.; McConnell, Joseph P.; Lennon, Ryan J.; Bryant, Sandra C.; Peterson, Lisa M.; Berger, Peter B.; Somers, Virend; Highsmith, W. Edward
PUB. DATE
March 2007
SOURCE
Mayo Clinic Proceedings;Mar2007, Vol. 82 Issue 3, p301
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To determine whether either of the gene variants associated with age-related macular degeneration is associated with coronary artery disease (CAD). PATIENTS AND METHODS: This study consisted of 493 patients who underwent clinically indicated coronary angiography between June 1, 1998, and January 1, 1999. The Y402H variant of the complement factor H (CFH) gene and the A69S variant of the LOC387715 gene locus were examined by restriction fragment length polymorphism. Multiple logistic regression models were used to assess the association of CFH and LOC gene variants with CAD. Covarlates with well-established associations with CAD were also evaluated. RESULTS: Seventy patients (14%) were homozygous for the histidine variant (HH) of CFH, 237 (48%) were heterozygous for the histidine variant (HY), and 186 (38%) were homozygous for the tyrosine variant (YY). Three hundred eight patients (62%) were homozygous for the alanine allele of L0C387715, 170 (34%) were heterozygous for Ala and Ser alleles, and 15 (3%) were homozygous for the serine variant. The overall association of the CFH genotype with CAD was not statistically significant (P=.08). However, some evidence (P=.046) suggested that CAD was Increased for the HH genotype compared to the homozygous wild-type YY genotype (odds ratio, 1.95; 95% confidence interval, 1.01-3.76). Male sex, hypertension, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and age were other variables that demonstrated significant associations with CAD. The overall effect of the LOC genotype was not statistically significant (P=.06). Heterozygosity for the serine variant was (P=.02) associated with the absence of CAD vs the AS genotype (odds ratio, 0.59; confidence interval, 0.38-0.91; P=.02). CONCLUSION: The CFH genotype may have an independent association with CAD, although our evidence did not show statistical significance. Controlling for known risk factors, the age-related macular degeneration-associated HH variant appears to be associated with CAD. The L0C387715 gene may also play a role in CAD.
ACCESSION #
24315248

 

Related Articles

  • Age-Related Macular Degeneration and the Incidence of Cardiovascular Disease: A Systematic Review and Meta-Analysis. Wu, Juan; Uchino, Miki; Sastry, Srinivas M.; Schaumberg, Debra A. // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Importance: Research has indicated some shared pathogenic mechanisms between age-related macular degeneration (AMD) and cardiovascular disease (CVD). However, results from prior epidemiologic studies have been inconsistent as to whether AMD is predictive of future CVD risk. Objective: To...

  • Selected literature.  // Formulary;Feb2006, Vol. 41 Issue 2, p96 

    The article presents several research studies in the field of medicine in the U.S. A study on the efficacy and safety of a fixed combination of travoprost 0.004 percent/timolol 0.5 percent ophthalmic solution once daily for open-angle glaucoma or ocular hypertension was conducted by J.S....

  • Eptifibatide and tirofiban prescribed appropriately in Spain.  // PharmacoEconomics & Outcomes News;4/10/2004, Issue 450, p6 

    Discusses research being done on tirofiban and eptifibatide treatment of patients with acute coronary syndrome with non-sinus tachycardia segment elevation. Reference to a study by N. Corominas and colleagues, published in the February 2004 issue of "Pharmacy World and Science" journal;...

  • Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes. Keech, A. // Evidence Based Medicine;Jun2006, Vol. 11 Issue 3, p86 

    The article presents a research that examines the effect of long term fenofibrate therapy on coronary heart disease events in patients with type 2 diabetes mellitus. In this study, patients aged 50 to 75 years who diagnosed of type 2 diabetes with no clear indication for lipid modifying therapy...

  • Treatment Approaches.  // Current Medical Literature: Cardiology;2007, Vol. 26 Issue 3, p80 

    The article discusses research related to approaches in medical treatment. It includes "The Final 10-Year Follow-Up Results From the BARI Randomized Trial," by BARI Investigators, "Optical Medical Therapy With or Without PCI for Stable Coronary Disease," by W. E. Boden, R. A. O'Rourke and K. K....

  • Genetic variants of Complement factor H gene are not associated with premature coronary heart disease: a family-based study in the Irish population. Weihua Meng; Hughes, Anne; Patterson, Chris C.; Belton, Christine; Kamaruddin, Muhammad S.; Horan, Paul G.; Kee, Frank; McKeown, Pascal P. // BMC Medical Genetics;2007, Vol. 8, p62 

    Background: The complement factor H (CFH) gene has been recently confirmed to play an essential role in the development of age-related macular degeneration (AMD). There are conflicting reports of its role in coronary heart disease. This study was designed to investigate if, using a family-based...

  • Blue-blocking lOLs may not be the panacea expected. Charters, Lynda // Ophthalmology Times;10/15/2005, Vol. 30 Issue 20, p27 

    Reports on the argument of researcher Martin Mainster against the use of blue-blocking IOLs to protect against age-related macular degeneration (AMD) presented at the European Society of Cataract and Refractive Surgeons meeting in Lisbon, Portugal. Explanation of Mainster on the two types of...

  • Taligen Gets $65M for Complement Programs.  // Bioworld Week;2/11/2008, Vol. 16 Issue 6, p2 

    The article reports on the complement programs of Taligen Therapeutics Inc. in Aurora, Colorado which could benefit the company as much as $65 million. The funding will allow the company to complete preclinical work and move into clinical trials with its drug candidates targetting complement...

  • Murmurs about the heart. Laborde, Karen L. // New Orleans Magazine;Feb2000, Vol. 34 Issue 5, p28 

    Focuses on the prevention and treatment of coronary-artery disease. INSET: Risk Factors for Coronary-Artery Disease.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics